GW Pharmaceuticals plc, of Porton Down, UK, received commercial approval for lead cannabinoid product Sativex in Italy for moderate to severe spasticity in multiple sclerosis patients who have not responded adequately to other anti-spasticity medications...In other news, closed its initial public offering (IPO) of 3.5 million American depository shares (ADSs) at $8.90 per share...PM01183 is designed to bind covalently to the minor groove of DNA to induce a specific degradation in tumor cells of RNA

Even after the news broke Monday – and the Theravance share price (NASDAQ:THRX) gained more than 14 percent to hit $40 – the entire company was still only valued at $3.94 billion...Editor's note: To obtain a CD of the webinar, "Royalty Financing for Biotech and Medical Device Companies: How to Determine Eligibility and Take Advantage of this Unique Financing Opportunity" or for a deeper dive, BioWorld's Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking, call 800-477-6307

Even after the news broke Monday – and the Theravance share price (NASDAQ:THRX) gained more than 14 percent to hit $40 – the entire company was still only valued at $3.94 billion...Editor's note: To obtain a CD of the webinar, "Royalty Financing for Biotech and Medical Device Companies: How to Determine Eligibility and Take Advantage of this Unique Financing Opportunity" or for a deeper dive, BioWorld's Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking, call 800-477-6307

rights to market Pertzye (pancrelipase) for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis...The board is recommending that shareholders approve the arrangement resolution, which is intended, among other goals, to improve Mirati's ability to attract funding in the larger U.S

turned its attention to other candidates in its pipeline...continue to view shares as undervalued based on the >$1B potential of ISIS-SMN-Rx, as well as the promise of ISIS-TTR-Rx and Isis' 20+ other pipeline candidates," he wrote...In other earnings news

In other news, Addex said dipraglurant demonstrated dose-dependent mGlu5 receptor occupancy in a nonhuman primate positron emission tomography study, showing the correlation between the plasma concentration of dipraglurant and occupancy of dipraglurant on mGlu5 receptors in the brain...Antisense Therapeutics Ltd., of Victoria, Australia, said it inked a deal for contract research organization Pharmaron in China to conduct a chronic, six-month toxicology study to support a future Phase IIb trial of

GW Pharmaceuticals plc, of Porton Down, UK, received commercial approval for lead cannabinoid product Sativex in Italy for moderate to severe spasticity in multiple sclerosis patients who have not responded adequately to other anti-spasticity medications

Antisense Therapeutics Ltd., of Victoria, Australia, said it inked a deal for contract research organization Pharmaron in China to conduct a chronic, six-month toxicology study to support a future Phase IIb trial of ATL1102, a drug targeting VLA-4, in multiple sclerosis patients...In separate news, Hyperion said it exercised its option to acquire Buphenyl (sodium phenylbutyrate) tablets and powder, an FDA-approved therapy for the chronic management of the most prevalent UCDs, and Ammonul (sodium

to begin a Phase IIa trial of BL-8040, a selective antagonist of chemokine receptor CXCR4, in acute myeloid leukemia (AML...In other news, GSK experienced manufacturing delays for manufacture and supply of Horizant (gabapentin enacarbil), partnered with XenoPort Inc., of Santa Clara, Calif., resulting in a stockout of the drug...Merck KGgA, of Darmstadt, Germany, reported that a collaboration agreement between its subsidiary, EMD Serono Inc., and Pfizer Inc., of New York, inked in July 2002 for the co

Merck KGgA, of Darmstadt, Germany, reported that a collaboration agreement between its subsidiary, EMD Serono Inc., and Pfizer Inc., of New York, inked in July 2002 for the co-promotion of multiple sclerosis drug Rebif (interferon beta-1a) extends until Dec. 31, 2015, according to an appellate court ruling...EMD Serono had contended that the collaboration should end on Dec. 31, 2013, and has asked the court to reconsider its ruling...In separate news, Merck Serono SA, of Geneva, a division of Merck

According to the terms, Shasun will be able to use the Debiopharm technology to manufacture synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets...Advancements from the project are expected to enable rapid and efficient delivery of Inovio's SynCon vaccines for universal flu, HIV and other infectious diseases

In other news, Prana reported that it received a A$2.5 million (US$2.6 million) cash refund under the R&D Tax Incentive Program...The refund was received to support research and clinical development of PBT2 for Huntington's and Alzheimer's diseases, as well as for other Prana research activities into Parkinson's disease and other neurological indications

Anacor also will create an expanded library of boron compounds to screen for additional potential drug candidates to treat neglected diseases and will provide access to the expanded library to the Gates Foundation and others, including academic, governmental and other nonprofit institutions or equivalent entities...The spinout is intended to split the clinical RVX-208 program from the epigenetics platform to create distinct corporate environments so Resverlogix is structurally ready for acquisition

plc's interest in Tysabri (natalizumab) and has gained full strategic, commercial and decision-making rights to the multiple sclerosis drug...SionX is designed to enable high-density expression of recombinant human ion channels on the cell membranes of Tetrahymena thermophile

Sosei licensed Japanese rights to the compound from BioAlliance, which markets the product as Loramyc/Oravig...The studies are designed to allow PCT to evaluate the applicability of SistemQC technology in stem cell characterization employing Sistemic's miRNA profiling system and analytical approaches to product miRNA panels

In other news, Elan said its Tysabri (natalizumab) restructuring transaction is set to close with Weston, Mass.-based Biogen Idec Inc...Elan and Biogen agreed last month for Biogen to buy all rights to the multiple sclerosis drug from Elan in a $3.25 billion deal that includes contingent payments

Celtic Therapeutics Management LLLP, of New York, changed its name to Auven Therapeutics Management LLLP to overcome confusion related to other Celtic entities...Elan and Biogen agreed last month for Biogen to buy all rights to the multiple sclerosis drug from Elan in a $3.25 billion deal that includes contingent payments. (See BioWorld Today, Feb. 13, 2013

plc to the blockbuster multiple sclerosis (MS) therapy Tysabri (natalizumab) didn't take long for analysts to applaud, though Wall Street traders spent time digesting the $3.25 billion deal, which includes contingent payments

plc to the blockbuster multiple sclerosis (MS) therapy Tysabri (natalizumab) didn't take long for analysts to applaud, though Wall Street traders spent time digesting the $3.25 billion deal, which includes contingent payments